Profile data is unavailable for this security.
About the company
BenevolentAI SA is engaged in creating and applying artificial intelligence (AI) and machine learning in drug discovery. The Company designs its technology to enable scientists to better understand the development of disease mechanisms, discover drug targets and make decisions. It serves patients by leveraging its proprietary and validated Benevolent Platform that integrates AI and science to uncover new biology, predict novel targets and develop drugs for complex diseases. The Benevolent Platform integrates technology, processes, and humans for faster research and development success. Its pipeline includes BEN-8744, BEN-28010, BEN-34712, Parkinson's disease, and Fibrosis. BEN-8744 is developed for the treatment of an ulcerative colitis. The Company provides scientists with a view of disease biology by integrating across all the domains and diverse data types, including omics, molecules, experimental data, literature, pathology, and biological systems.
- Revenue in EUR (TTM)5.81m
- Net income in EUR-61.35m
- Incorporated2021
- Employees248.00
- LocationBenevolentAI SA4-8 Maple StreetLONDON W1T 5HDUnited KingdomGBR
- Phone+44 203 781 9360
- Websitehttps://www.benevolent.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adocia SA | 2.15m | -21.16m | 85.30m | 78.00 | -- | -- | -- | 39.67 | -1.93 | -1.93 | 0.194 | -0.4908 | 0.0774 | 2.62 | 7.44 | 27,564.10 | -76.16 | -43.08 | -396.14 | -72.93 | 7.91 | -- | -984.28 | -514.53 | 1.01 | -2.07 | 2.12 | -- | -81.22 | -46.13 | -206.65 | -- | -27.60 | -- |
| Alligator Bioscience AB | 4.02m | -20.63m | 88.24m | 51.00 | -- | -- | -- | 21.93 | -0.362 | -0.362 | 0.0696 | -0.0125 | 0.2653 | -- | 9.47 | 788,034.50 | -136.02 | -73.26 | -367.94 | -91.33 | -- | -- | -512.61 | -811.68 | -- | -35.61 | 5.17 | -- | 62.78 | 16.60 | -28.53 | -- | -20.34 | -- |
| Inventiva SA | 17.48m | -110.43m | 94.46m | 112.00 | -- | -- | -- | 5.40 | -2.45 | -2.45 | 0.3854 | -0.6146 | 0.1884 | -- | 9.18 | 156,044.60 | -116.84 | -54.30 | -207.08 | -69.98 | -- | -- | -620.31 | -669.97 | 0.9524 | -19.98 | 6.96 | -- | 43.50 | 40.46 | -103.46 | -- | -0.33 | -- |
| Anatolia TaniveBytklj Unli Ar Ge SiveTiA | 8.02m | -5.48m | 96.32m | 229.00 | -- | 2.79 | -- | 12.01 | -0.5563 | -0.5563 | 1.85 | 5.98 | 0.2549 | 0.3473 | 4.29 | 1,490,227.00 | -17.42 | 16.60 | -18.36 | 17.72 | 80.55 | 85.88 | -68.34 | 39.69 | 5.78 | -- | 0.0142 | -- | -49.14 | 72.60 | -548.82 | -- | 65.06 | -- |
| Maat Pharma SA | 2.23m | -19.72m | 102.16m | 50.00 | -- | 4.17 | -- | 45.85 | -1.73 | -1.73 | 0.196 | 1.76 | 0.0508 | 4.84 | 4.16 | 44,560.00 | -44.99 | -35.49 | -58.93 | -42.98 | 74.28 | -- | -884.96 | -1,157.54 | 2.76 | -49.61 | 0.4075 | -- | 55.80 | -- | -43.78 | -- | 30.30 | -- |
| Scope Fluidics SA | 21.78k | -5.29m | 104.71m | 40.00 | -- | 6.03 | -- | 4,807.02 | -8.29 | -8.29 | 0.0341 | 27.18 | 0.0009 | 2.94 | 0.0337 | 2,325.00 | -21.76 | 52.74 | -22.74 | 57.32 | -2,022.58 | -420.87 | -24,304.30 | 30,134.78 | 13.86 | -- | 0.0299 | -- | 27.72 | -- | -105.76 | -- | 89.99 | -- |
| Eurofins-Cerep SA | 44.07m | 7.64m | 107.94m | 228.00 | 14.13 | 1.67 | 11.23 | 2.45 | 1,514.43 | 1,514.43 | 8,743.94 | 12,820.37 | 0.5864 | 1.67 | 5.08 | 193,287.10 | 10.16 | 14.21 | 12.22 | 17.51 | 85.01 | 73.61 | 17.33 | 19.77 | 4.87 | -- | 0.00005 | -- | -7.47 | 11.60 | -33.72 | 14.64 | -- | -- |
| Heidelberg Pharma AG | 9.52m | -13.06m | 109.52m | 97.00 | -- | 2.66 | -- | 11.50 | -0.2837 | -0.2837 | 0.2062 | 0.8832 | 0.1270 | 0.194 | 13.23 | 100,234.60 | -17.42 | -43.91 | -22.34 | -64.34 | 82.74 | 52.13 | -137.16 | -206.24 | 4.90 | -- | 0.3417 | -- | -46.75 | 21.87 | -3.27 | -- | -0.8341 | -- |
| BenevolentAI SA | 5.81m | -61.35m | 111.26m | 248.00 | -- | 1.13 | -- | 19.15 | -0.5111 | -0.5111 | 0.0484 | 0.6886 | 0.0401 | -- | 0.1712 | 23,425.98 | -42.37 | -- | -50.50 | -- | -14.73 | -- | -1,056.02 | -- | -- | -- | 0.0594 | -- | -30.58 | -- | 61.38 | -- | -- | -- |
| Egetis Therapeutics AB (publ) | 8.27m | -26.10m | 118.25m | 32.00 | -- | 3.34 | -- | 14.30 | -1.23 | -1.23 | 0.3884 | 1.37 | 0.1496 | 13.45 | 7.48 | 3,477,778.00 | -33.65 | -33.02 | -40.07 | -36.46 | 92.12 | -- | -224.92 | -357.72 | 1.55 | -24.39 | 0.2158 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
| XSpray Pharma AB (publ) | 0.00 | -18.91m | 118.76m | 26.00 | -- | 2.48 | -- | -- | -7.05 | -7.05 | 0.00 | 19.79 | 0.00 | -- | -- | 0.00 | -33.11 | -18.38 | -36.76 | -19.26 | -- | -- | -- | -- | 3.50 | -- | 0.0496 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
| Oryzon Genomics SA | 0.00 | -3.82m | 119.24m | 43.00 | -- | 1.34 | -- | -- | -0.0597 | -0.0597 | 0.00 | 1.37 | 0.00 | 153.65 | -- | 0.00 | -3.55 | -4.20 | -4.13 | -4.82 | -- | -- | -- | -- | 0.9495 | -3.54 | 0.134 | -- | -- | -- | 20.76 | -- | 15.52 | -- |
| Diamyd Medical AB | 16.38k | -12.29m | 123.46m | 25.00 | -- | 7.39 | -- | 7,537.94 | -1.55 | -1.55 | 0.0021 | 1.96 | 0.0009 | -- | 3.35 | 7,440.00 | -68.99 | -25.46 | -76.65 | -28.37 | -7,386.02 | -1,419.23 | -75,065.59 | -5,896.43 | -- | -90.74 | 0.1391 | -- | 20.26 | -5.54 | -12.13 | -- | -- | -- |
| Futura Medical PLC | 10.02m | -4.48m | 129.33m | 12.00 | -- | 13.88 | -- | 12.90 | -0.0126 | -0.0126 | 0.0272 | 0.0259 | 0.8538 | 5,710.27 | 7.20 | 699,850.80 | -38.14 | -79.25 | -47.43 | -127.22 | 67.70 | -- | -44.68 | -914.37 | 3.75 | -- | 0.00 | -- | -- | -- | -11.40 | -- | 219.68 | -- |
| Nightingale Health Oyj | 3.65m | -18.06m | 133.33m | 81.00 | -- | 2.22 | -- | 36.49 | -0.2979 | -0.2979 | 0.0603 | 1.50 | 0.0344 | 1.60 | 3.87 | 44,560.98 | -17.02 | -14.20 | -18.12 | -15.69 | 75.81 | 83.57 | -494.25 | -408.50 | 14.15 | -- | 0.0378 | -- | 80.80 | 19.05 | -12.38 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to BenevolentAI SA's reporting currency: Euro EUR
5.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Link Fund Solutions Ltd.as of 13 Sep 2024 | 7.11m | 4.98% |
| Mirova SA (Investment Management)as of 31 Jul 2024 | 1.28m | 0.90% |
| DNCA Finance SAas of 31 Dec 2023 | 0.00 | 0.00% |
Data from 31 May 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
